From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy
Abstract Liver cirrhosis, a chronic disease distinguished by extensive scarring in the liver, results in liver dysfunction and fatal complications such as portal hypertension and liver cancer. Although early interventions can retard or reverse early injury, advanced stages often call for liver trans...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-025-04535-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344381990993920 |
|---|---|
| author | Vida Bozorgi Mahnaz Babaahmadi Mohammad Salehi Jamshid Vafaeimanesh Ensiyeh Hajizadeh-Saffar |
| author_facet | Vida Bozorgi Mahnaz Babaahmadi Mohammad Salehi Jamshid Vafaeimanesh Ensiyeh Hajizadeh-Saffar |
| author_sort | Vida Bozorgi |
| collection | DOAJ |
| description | Abstract Liver cirrhosis, a chronic disease distinguished by extensive scarring in the liver, results in liver dysfunction and fatal complications such as portal hypertension and liver cancer. Although early interventions can retard or reverse early injury, advanced stages often call for liver transplantation—a therapy undermined by donor shortage and logistical setbacks. Emerging cell therapies, particularly those based on mesenchymal stem cells (MSCs), offer a novel approach to addressing these clinical needs. MSCs, self-renewing multipotent stromal cells, can differentiate into many cell types, including hepatocyte-like cells. Immune regulation, regenerative signaling, and anti-scarring effects are three mechanisms that underlie their therapeutic promise. MSCs modulate immune cells, suppressing inflammation and promoting tissue healing. MSCs release several growth factors and cytokines, including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and matrix metalloproteinases (MMPs), which participate in tissue regeneration. Among these, HGF is bivalent, as it supports hepatocyte proliferation while also inhibiting fibrosis and apoptosis, thereby allowing the tissue to repair and protect itself. Recent advances identify extracellular vesicles from MSCs (MSC-EVs) as a cell-free alternative. The vesicles contain bioactive cargo, including microRNAs and proteins, that regulate immune function, inhibit cell death, and facilitate liver repair. Preclinical models of cirrhosis in animals have demonstrated MSC-EVs to enhance liver function, reduce scarring, and improve survival. This review integrates current knowledge of MSC-based therapies, their mechanisms, clinical potential, and challenges associated with their deployment. More than 50 clinical trials are registered or planned to evaluate MSC-based treatments for liver cirrhosis. Preclinical and clinical outcomes are encouraging; however, further work is needed to optimize delivery strategies, confirm safety, and facilitate the universal clinical use of this approach. Advances in MSC-guided regenerative medicine have the potential to revolutionize therapy for end-stage liver disease, offering hope where traditional treatments fail. |
| format | Article |
| id | doaj-art-f45a3ef1fb6d44dfb8bf5b85532e9387 |
| institution | Kabale University |
| issn | 1757-6512 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj-art-f45a3ef1fb6d44dfb8bf5b85532e93872025-08-20T03:42:40ZengBMCStem Cell Research & Therapy1757-65122025-08-0116111610.1186/s13287-025-04535-8From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapyVida Bozorgi0Mahnaz Babaahmadi1Mohammad Salehi2Jamshid Vafaeimanesh3Ensiyeh Hajizadeh-Saffar4Clinical Research Development Center, Qom University of Medical SciencesAdvanced Therapy Medicinal Product Technology Development Center (ATMP-TDC), Royan Institute for Stromal Cell Biology and Technology, ACECRClinical Research Development Center, Qom University of Medical SciencesClinical Research Development Center, Qom University of Medical SciencesAdvanced Therapy Medicinal Product Technology Development Center (ATMP-TDC), Royan Institute for Stromal Cell Biology and Technology, ACECRAbstract Liver cirrhosis, a chronic disease distinguished by extensive scarring in the liver, results in liver dysfunction and fatal complications such as portal hypertension and liver cancer. Although early interventions can retard or reverse early injury, advanced stages often call for liver transplantation—a therapy undermined by donor shortage and logistical setbacks. Emerging cell therapies, particularly those based on mesenchymal stem cells (MSCs), offer a novel approach to addressing these clinical needs. MSCs, self-renewing multipotent stromal cells, can differentiate into many cell types, including hepatocyte-like cells. Immune regulation, regenerative signaling, and anti-scarring effects are three mechanisms that underlie their therapeutic promise. MSCs modulate immune cells, suppressing inflammation and promoting tissue healing. MSCs release several growth factors and cytokines, including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and matrix metalloproteinases (MMPs), which participate in tissue regeneration. Among these, HGF is bivalent, as it supports hepatocyte proliferation while also inhibiting fibrosis and apoptosis, thereby allowing the tissue to repair and protect itself. Recent advances identify extracellular vesicles from MSCs (MSC-EVs) as a cell-free alternative. The vesicles contain bioactive cargo, including microRNAs and proteins, that regulate immune function, inhibit cell death, and facilitate liver repair. Preclinical models of cirrhosis in animals have demonstrated MSC-EVs to enhance liver function, reduce scarring, and improve survival. This review integrates current knowledge of MSC-based therapies, their mechanisms, clinical potential, and challenges associated with their deployment. More than 50 clinical trials are registered or planned to evaluate MSC-based treatments for liver cirrhosis. Preclinical and clinical outcomes are encouraging; however, further work is needed to optimize delivery strategies, confirm safety, and facilitate the universal clinical use of this approach. Advances in MSC-guided regenerative medicine have the potential to revolutionize therapy for end-stage liver disease, offering hope where traditional treatments fail.https://doi.org/10.1186/s13287-025-04535-8Mesenchymal stem cellsLiver cirrhosisMSC-EVsMSC |
| spellingShingle | Vida Bozorgi Mahnaz Babaahmadi Mohammad Salehi Jamshid Vafaeimanesh Ensiyeh Hajizadeh-Saffar From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy Stem Cell Research & Therapy Mesenchymal stem cells Liver cirrhosis MSC-EVs MSC |
| title | From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy |
| title_full | From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy |
| title_fullStr | From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy |
| title_full_unstemmed | From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy |
| title_short | From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy |
| title_sort | from signaling pathways to clinical trials mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy |
| topic | Mesenchymal stem cells Liver cirrhosis MSC-EVs MSC |
| url | https://doi.org/10.1186/s13287-025-04535-8 |
| work_keys_str_mv | AT vidabozorgi fromsignalingpathwaystoclinicaltrialsmesenchymalstemcellsasmultimodalregenerativearchitectsinlivercirrhosistherapy AT mahnazbabaahmadi fromsignalingpathwaystoclinicaltrialsmesenchymalstemcellsasmultimodalregenerativearchitectsinlivercirrhosistherapy AT mohammadsalehi fromsignalingpathwaystoclinicaltrialsmesenchymalstemcellsasmultimodalregenerativearchitectsinlivercirrhosistherapy AT jamshidvafaeimanesh fromsignalingpathwaystoclinicaltrialsmesenchymalstemcellsasmultimodalregenerativearchitectsinlivercirrhosistherapy AT ensiyehhajizadehsaffar fromsignalingpathwaystoclinicaltrialsmesenchymalstemcellsasmultimodalregenerativearchitectsinlivercirrhosistherapy |